Health Blueprint

Back to Longevity News

News summary

Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body

Source: Nature - Main • Published: 12 Nov 2026, 00:00

Summarized by Masters of Longevity from Nature - Main.

Lonvo-z maintained effectiveness four years after one infusion, Intellia reported.

Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body
Key Takeaways
  • Lonvo-z is designed to disable prekallikrein production in liver.
  • In vivo editing was reported to carry added safety concerns.
  • Clinical causality for long-term safety has not been established.
Read the full article at Nature - Main ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.